Compare DAN & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAN | CRNX |
|---|---|---|
| Founded | 1904 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2002 | 2018 |
| Metric | DAN | CRNX |
|---|---|---|
| Price | $31.21 | $84.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $40.60 | ★ $76.75 |
| AVG Volume (30 Days) | 1.4M | ★ 2.5M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 264.10 | N/A |
| EPS | ★ 9.93 | N/A |
| Revenue | ★ $7,500,000,000.00 | $1,039,000.00 |
| Revenue This Year | $1.89 | $720.10 |
| Revenue Next Year | $4.59 | $184.67 |
| P/E Ratio | $3.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.74 | $28.73 |
| 52 Week High | $39.56 | $84.80 |
| Indicator | DAN | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Dana Inc is provider of products to virtually every vehicle manufacturer in the world. Its technologies include drive systems (axles, driveshafts and transmissions); electrodynamic technologies (motors, inverters, software and control systems, battery-management systems, and fuel cell plates); sealing solutions (gaskets, seals, cam covers, and oil pan modules); thermal-management technologies (transmission and engine oil cooling, battery and electronics cooling, charge air cooling, and thermal-acoustical protective shielding); and digital solutions (active and passive system controls and descriptive and predictive analytics). The company has two operating segments: Light Vehicle and Commercial Vehicle. The Light Vehicles segment generates the majority of revenue.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.